IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i7p4166-d784465.html
   My bibliography  Save this article

The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment

Author

Listed:
  • Giovanna Elisa Calabrò

    (Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
    VIHTALI (Value in Health Technology and Academy for Leadership & Innovation), Spin Off of Università Cattolica del Sacro Cuore, 00168 Rome, Italy)

  • Sara Boccalini

    (Department of Health Sciences, University of Florence, 50121 Florence, Italy)

  • Donatella Panatto

    (Department of Health Sciences, University of Genoa, 16132 Genoa, Italy)

  • Caterina Rizzo

    (Clinical Pathways and Epidemiology Unit-Medical Direction, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy)

  • Maria Luisa Di Pietro

    (Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 00168 Rome, Italy)

  • Fasika Molla Abreha

    (Graduate School of Health Economics and Management, Università Cattolica del Sacro Cuore, 00168 Rome, Italy)

  • Marco Ajelli

    (Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN 47405, USA)

  • Daniela Amicizia

    (Department of Health Sciences, University of Genoa, 16132 Genoa, Italy)

  • Angela Bechini

    (Department of Health Sciences, University of Florence, 50121 Florence, Italy)

  • Irene Giacchetta

    (Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy)

  • Piero Luigi Lai

    (Department of Health Sciences, University of Genoa, 16132 Genoa, Italy)

  • Stefano Merler

    (Center for Health Emergencies, Bruno Kessler Foundation, 38122 Trento, Italy)

  • Chiara Primieri

    (Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy)

  • Filippo Trentini

    (Center for Health Emergencies, Bruno Kessler Foundation, 38122 Trento, Italy
    Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, 20136 Milan, Italy)

  • Sara Violi

    (Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy)

  • Paolo Bonanni

    (Department of Health Sciences, University of Florence, 50121 Florence, Italy)

  • Chiara de Waure

    (Department of Medicine and Surgery, University of Perugia, 06123 Perugia, Italy)

Abstract

Background. The elderly, commonly defined as subjects aged ≥65 years, are among the at-risk subjects recommended for annual influenza vaccination in European countries. Currently, two new vaccines are available for this population: the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose quadrivalent influenza vaccine (hdQIV). Their multidimensional assessment might maximize the results in terms of achievable health benefits. Therefore, we carried out a Health Technology Assessment (HTA) of the aQIV by adopting a multidisciplinary policy-oriented approach to evaluate clinical, economic, organizational, and ethical implications for the Italian elderly. Methods. A HTA was conducted in 2020 to analyze influenza burden; characteristics, efficacy, and safety of aQIV and other available vaccines for the elderly; cost-effectiveness of aQIV; and related organizational and ethical implications. Comprehensive literature reviews/analyses were performed, and a transmission model was developed in order to address the above issues. Results. In Italy, the influenza burden on the elderly is high and from 77.7% to 96.1% of influenza-related deaths occur in the elderly. All available vaccines are effective and safe; however, aQIV, such as the adjuvanted trivalent influenza vaccine (aTIV), has proved more immunogenic and effective in the elderly. From the third payer’s perspective, but also from the societal one, the use of aQIV in comparison with egg-based standard QIV (eQIV) in the elderly population is cost-effective. The appropriateness of the use of available vaccines as well as citizens’ knowledge and attitudes remain a challenge for a successful vaccination campaign. Conclusions. The results of this project provide decision-makers with important evidence on the aQIV and support with scientific evidence on the appropriate use of vaccines in the elderly.

Suggested Citation

  • Giovanna Elisa Calabrò & Sara Boccalini & Donatella Panatto & Caterina Rizzo & Maria Luisa Di Pietro & Fasika Molla Abreha & Marco Ajelli & Daniela Amicizia & Angela Bechini & Irene Giacchetta & Piero, 2022. "The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment," IJERPH, MDPI, vol. 19(7), pages 1-14, March.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:7:p:4166-:d:784465
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/7/4166/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/7/4166/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement," PharmacoEconomics, Springer, vol. 31(5), pages 361-367, May.
    2. Anke L Stuurman & Caterina Rizzo & Mendel Haag, 2021. "Investigating the procurement system for understanding seasonal influenza vaccine brand availability in Europe," PLOS ONE, Public Library of Science, vol. 16(4), pages 1-12, April.
    3. Carlo Federici & Marianna Cavazza & Francesco Costa & Claudio Jommi, 2018. "Health care costs of influenza-related episodes in high income countries: A systematic review," PLOS ONE, Public Library of Science, vol. 13(9), pages 1-15, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
    2. Clarke, Lorcan, 2020. "An introduction to economic studies, health emergencies, and COVID-19," LSE Research Online Documents on Economics 105051, London School of Economics and Political Science, LSE Library.
    3. Najmiatul Fitria & Antoinette D. I. Asselt & Maarten J. Postma, 2019. "Cost-effectiveness of controlling gestational diabetes mellitus: a systematic review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 407-417, April.
    4. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    5. Thomas Grochtdreis & Hans-Helmut König & Alexander Dobruschkin & Gunhild von Amsberg & Judith Dams, 2018. "Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-25, December.
    6. Wendy Hens & Dirk Vissers & Nick Verhaeghe & Jan Gielen & Luc Van Gaal & Jan Taeymans, 2021. "Unsupervised Exercise Training Was Not Found to Improve the Metabolic Health or Phenotype over a 6-Month Dietary Intervention: A Randomised Controlled Trial with an Embedded Economic Analysis," IJERPH, MDPI, vol. 18(15), pages 1-13, July.
    7. Kim Edmunds & Penny Reeves & Paul Scuffham & Daniel A. Galvão & Robert U. Newton & Mark Jones & Nigel Spry & Dennis R. Taaffe & David Joseph & Suzanne K. Chambers & Haitham Tuffaha, 2020. "Cost-Effectiveness Analysis of Supervised Exercise Training in Men with Prostate Cancer Previously Treated with Radiation Therapy and Androgen-Deprivation Therapy," Applied Health Economics and Health Policy, Springer, vol. 18(5), pages 727-737, October.
    8. Andrew Gawron & Dustin French & John Pandolfino & Colin Howden, 2014. "Economic Evaluations of Gastroesophageal Reflux Disease Medical Management," PharmacoEconomics, Springer, vol. 32(8), pages 745-758, August.
    9. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
    10. Frank G. Sandmann & Julie V. Robotham & Sarah R. Deeny & W. John Edmunds & Mark Jit, 2018. "Estimating the opportunity costs of bed‐days," Health Economics, John Wiley & Sons, Ltd., vol. 27(3), pages 592-605, March.
    11. Jesse Elliott & Sasha Katwyk & Bláthnaid McCoy & Tammy Clifford & Beth K. Potter & Becky Skidmore & George A. Wells & Doug Coyle, 2019. "Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations," PharmacoEconomics, Springer, vol. 37(10), pages 1261-1276, October.
    12. Wei Zhang & Aslam Anis, 2014. "Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now," PharmacoEconomics, Springer, vol. 32(5), pages 425-427, May.
    13. Katherine Edwards & Natasha Jones & Julia Newton & Charlie Foster & Andrew Judge & Kate Jackson & Nigel K. Arden & Rafael Pinedo-Villanueva, 2017. "The cost-effectiveness of exercise-based cardiac rehabilitation: a systematic review of the characteristics and methodological quality of published literature," Health Economics Review, Springer, vol. 7(1), pages 1-23, December.
    14. Don Husereau & Michael Drummond & Stavros Petrou & Dan Greenberg & Josephine Mauskopf & Federico Augustovski & Andrew Briggs & David Moher & Elizabeth Loder & Chris Carswell, 2015. "Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration," PharmacoEconomics, Springer, vol. 33(5), pages 535-536, May.
    15. Nina van der Vliet & Anita W.M. Suijkerbuijk & Adriana T. de Blaeij & G. Ardine de Wit & Paul F. van Gils & Brigit A.M. Staatsen & Rob Maas & Johan J. Polder, 2020. "Ranking Preventive Interventions from Different Policy Domains: What Are the Most Cost-Effective Ways to Improve Public Health?," IJERPH, MDPI, vol. 17(6), pages 1-24, March.
    16. Simon van der Schans & Lucas M. A. Goossens & Melinde R. S. Boland & Janwillem W. H. Kocks & Maarten J. Postma & Job F. M. van Boven & Maureen P. M. H. Rutten-van Mölken, 2017. "Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendatio," PharmacoEconomics, Springer, vol. 35(1), pages 43-63, January.
    17. Andrew Briggs & Rachel Nugent, 2016. "Editorial," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 6-8, February.
    18. Don Husereau & Michael Drummond & Federico Augustovski & Esther Bekker-Grob & Andrew H. Briggs & Chris Carswell & Lisa Caulley & Nathorn Chaiyakunapruk & Dan Greenberg & Elizabeth Loder & Josephine Ma, 2022. "Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations," PharmacoEconomics, Springer, vol. 40(6), pages 601-609, June.
    19. Neily Zakiyah & Antoinette D I van Asselt & Frank Roijmans & Maarten J Postma, 2016. "Economic Evaluation of Family Planning Interventions in Low and Middle Income Countries; A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-19, December.
    20. Feng Xie & A. Pickard & Paul Krabbe & Dennis Revicki & Rosalie Viney & Nancy Devlin & David Feeny, 2015. "A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)," PharmacoEconomics, Springer, vol. 33(8), pages 867-877, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:7:p:4166-:d:784465. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.